A Pulmonary Hypertension Drug's Label Just Got a Major Data Upgrade
A Pulmonary Hypertension Drug's Label Just Got a Major Data Upgrade
The US Food and Drug Administration has approved an update to the prescribing information for Winrevair (sotatercept-csrk), Merck’s activin signalling inhibitor for pulmonary arterial hypertension (PAH). The revised label incorporates efficacy and safety results from the Phase 3 HYPERION trial, which evaluated the drug in adults diagnosed with PAH within the previous year. In that study, adding Winrevair to background therapy reduced the risk of clinical worsening by 76% compared with placebo. The update does not create a new indication; rather, it strengthens the evidence base for using the therapy earlier in the treatment course, including in patients already on multidrug regimens.
What HYPERION Showed
HYPERION enrolled adults with WHO Group 1 PAH who were in functional class II or III, had been diagnosed within 12 months of screening, and were at intermediate to high risk of progression. Participants received either sotatercept or placebo on top of their existing PAH background therapy. Over a median follow-up of roughly 13 months, clinical worsening events occurred in 10.6% of the sotatercept group versus 36.9% of the placebo group (hazard ratio 0.24; 95% CI 0.14–0.41; P < 0.001). The composite endpoint included death, unplanned PAH-related hospitalisation, atrial septostomy, lung transplantation, or a decline in six-minute walk distance accompanied by other signs of worsening.
Why Earlier Use Matters
PAH is a progressive disease in which delays in effective therapy can lead to right-heart failure and death. Traditional treatment algorithms often escalate therapy only after patients fail to reach low-risk status on initial regimens. Data supporting earlier addition of a therapy with a distinct mechanism—inhibition of the activin pathway rather than the classic prostacyclin, endothelin or nitric-oxide pathways—give clinicians stronger evidence for intervening before further deterioration. The label update explicitly places HYPERION results in the hands of prescribers considering Winrevair within the first year of diagnosis.
Safety Information Added to the Label
The revision also strengthens safety language. Winrevair is now contraindicated in patients with serious hypersensitivity (including anaphylaxis or angioedema) to sotatercept or any of its excipients; previously the label listed no contraindications. Common adverse events in HYPERION were consistent with the known profile and included epistaxis, telangiectasia and increased haemoglobin. Monitoring recommendations for haemoglobin and platelets remain in place.
Context Within Existing Approval
Winrevair was already approved to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events in adults with PAH. The original approval rested primarily on the STELLAR trial. HYPERION extends the evidence to a newly diagnosed, intermediate- to high-risk population receiving contemporary background therapy, reinforcing the drug’s role as an add-on across a broader segment of the treatment journey.
Implications for Clinical Practice
With the updated label, physicians have randomised data supporting earlier use of sotatercept alongside standard PAH therapies. European Respiratory Society guidance has already moved toward stronger endorsement of sotatercept as add-on therapy for intermediate-low to high-risk patients who have not achieved low-risk status. The US label change aligns the formal prescribing information more closely with that evolving practice pattern and with the goal of preventing clinical worsening rather than only reacting to it.
Outlook
The FDA’s incorporation of HYPERION data into the Winrevair label constitutes a meaningful upgrade for a therapy that has already changed the PAH treatment landscape. A 76% relative reduction in clinical worsening risk in recently diagnosed patients provides a clear rationale for considering the drug earlier. Continued real-world evidence and longer-term outcomes will further define its optimal place in multi-drug regimens, but the regulatory update itself gives clinicians and patients stronger, label-supported evidence for acting sooner in the course of this progressive disease.
Sources
Aluminium Nitrate
Found this useful?
